Shanghai Pharmaceuticals Holding Co., Ltd SHPMY · OTC
$6.45 -9.03% (-$0.64)
Summary
56 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
- It has been profitable 6 years in a row.
What to watch
- Out of every 100 CNY of revenue, only 1.8 CNY is left as net profit.
- It earns only 4.3 CNY a year on every 100 CNY of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 6.2 CNY for 1 CNY of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (CNY)
Diluted EPS (CNY)
- Analyst estimate
Revenue grew by 8.1% a year over 5 years. Over the last 3 years it grew by 6.9% a year. Earnings per share fell by 1.5% a year over the last 3 years.
Growth in detailDoes it make money?
PoorlyWhere 100 CNY of revenue goes
- Cost of sales 89 CNY
- Research and development 0.8 CNY
- Sales and administration 6.9 CNY
- Taxes and other 1.2 CNY
- Net profit 1.8 CNY
Net profit, industry median (Medical - Distribution) 1.4 CNY
Out of every 100 CNY of revenue, 1.8 CNY is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 7.2 years of free cash flow. Its debt is larger than its cash. The debt score is high even so.
Financial health in detailDoes it pay a dividend?
High, safe- Yield
- 5.14%
- Paid out of profit
- 32%
- Raised in a row
- 1 year
You receive $0.33 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.